Telatinib
| Title | Journal |
|---|---|
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. | Journal of medicinal chemistry 20121227 |
| The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds? | Arzneimittel-Forschung 20120401 |
| Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. | Annals of oncology : official journal of the European Society for Medical Oncology 20111101 |
| Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. | Journal of the National Cancer Institute 20110504 |
| Development of second-generation VEGFR tyrosine kinase inhibitors: current status. | Current oncology reports 20110401 |
| Targeted therapies for metastatic esophagogastric cancer. | Current treatment options in oncology 20110301 |
| Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. | Investigational new drugs 20110201 |
| Common secondary causes of resistant hypertension and rational for treatment. | International journal of hypertension 20110101 |
| Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. | Cardiology research and practice 20110101 |
| Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer. | Vascular cell 20110101 |
| Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. | European journal of medicinal chemistry 20101101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100901 |
| A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. | Journal of pharmacokinetics and pharmacodynamics 20100801 |
| Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. | Journal of the National Cancer Institute 20100505 |
| Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100401 |
| Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090901 |
| Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. | British journal of cancer 20081104 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20081001 |
| Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20070601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20070101 |